Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Renzapride reduces GI transit time, increases colonic motility in IBS patients and healthy subjects

Nov. 6, 2002

Incara divests liver cell program

Nov. 6, 2002

Beneficial effects of Z-338 in patients with functional dyspepsia

Nov. 4, 2002

Rectal administration of PL-14736 safe in first human study

Nov. 4, 2002

YH-1885 for one week significantly inhibits intragastric acidity in humans

Nov. 4, 2002

Effects of Enteryx on LES function in GERD patients

Nov. 4, 2002

New class of CpG oligonucleotides with promise for HCV infection

Oct. 31, 2002

Potent and gut-selective Ca2+ channel antagonist with potential in IBS

Oct. 30, 2002

Jerini initiates phase I trial of icatibant for decompensated liver cirrhosis

Oct. 29, 2002

Patient randomization completed in phase II liver fibrosis trial of Actimmune

Oct. 28, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...